

XVI CONGRESSO NAZIONALE GISMO Up-To-Date nell'Osteoporosi e nelle malattie dell'apparato Muscolo Scheletriche

Sarcopenia: criteri diagnostici e implicazioni scheletriche

Patrizia D'Amelio, MD, PhD

Service de Gériatrie et réadaptation gériatrique CHUV, Lausanne







AGENDA

- Sarcopenia: what are we talking about?
- Relationship between skeletal muscle and bone
- Sarcopenia a socio economic burden
- Conclusions






UNIL | Université de Lausanne

Sarcopenia

UNIL | Université de Lausanne Disease or normal aging?










Sarcopenia Changes in Muscle structure










Sarcopenic muscle function

UNIL | Université de Lausanne










Ethiologic factors in sarcopenia

UNIL | Université de Lausanne









Criteria for the diagnosis of sarcopenia







Criterium	Slowness	Weakness	Low lean mass	Summary definition
International Working Group	Gait speed <1.0 m/s	Notincluded	ALM/ht² ≤7.23 kg/m²	Sarcopenia: slowness and low lean mass
EWGSOP	Gait speed ≤0.8 m/s	Grip strength <30 kg	ALM/ht² ≤7.23 kg/m²	(1) Sarcopenia: low lean mass plus slowness or weakness
				(2) Severe sarcopenia: all three criteria
Cantro				C:UV



Criterium	Slowness	Weakness	Low lean mass	Summary definition
FNIH Sarcopenia Project primary definition	Gait speed ≤0.8 m/s	Grip strength <26 kg	ALM/body mass index <0.789	(1) Weakness and low lean mass
				(2) Slowness with weakness and low lean mass
Baumgartner	ND	ND	ALM/ht² ≤7.23 kg/m²	Low lean mass
Newman	ND	ND	Residual of actual ALM-predicted ALM from equation	Low lean mass







Criteria revised EWSGOP 2018

2018 operational definition of sarcopenia

Low muscle strength

Low muscle quantity or quality

Low physical performance

- Probable sarcopenia is identified by Criterion 1.
- Diagnosis is confirmed by additional documentation of Criterion 2.
- If Criteria 1, 2 and 3 are all met, sarcopenia is considered severe.







Low muscle strength

2018 operational definition of sarcopenia

Low muscle strength

Low muscle quantity or quality

Low physical performance

Variable	Clinical practice	Research studies	Reference	
Case finding	se finding SARC-F questionnaire SARC-F Ishii screening tool		Malmstrom <i>et</i> al. (2016)	
			Ishii <i>et al.</i> (2014)	
Skeletal muscle	Grip strength	Grip strength	Roberts <i>et al.</i> (2011)	
strength	Chair stand test (chair rise test)	Chair stand test (5-times sit-to-stand)	American Academy of Orthotists & Prosthetists	







SARC-F

Component	Question	Scoring
Strength	How much difficulty do you have in lifting and carrying 10 pounds?	None = 0 $Some = 1$ $A lot or unable = 2$
Assistance in walking	How much difficulty do you have walking across a room?	None = 0 Some = 1 A lot, use aids, or unable = 2
Rise from a chair	How much difficulty do you have transferring from a chair or bed?	None = 0 Some = 1 A lot or unable without help = 2
Climb stairs	How much difficulty do you have climbing a flight of 10 stairs?	None = 0 Some = 1 A lot or unable = 2
Falls	How many times have you fallen in the past year?	None = 0 1-3 falls = 1 4 or more falls = 2







Low muscle quantity or quality

2018 operational definition of sarcopenia

Low muscle strength

Low muscle quantity or quality

Low physical performance

Variable	Clinical practice	Research studies	Reference
Skeletal muscle mass or Skeletal muscle	Appendicular skeletal muscle mass (ASMM) by Dual-energy X-ray absorptiometry (DXA)	ASMM by DXA	Schweitzer (2015) Mitsiopoulos (1998)
quality	Whole-body skeletal muscle mass (SMM) or ASMM predicted by Bioelectrical impedance analysis (BIA)	Whole-body SMM or ASMM by Magnetic Resonance Imaging (MRI, total body protocol)	Shen (2004) Sergi (2017)
Skeletal muscle strength	Grip strength	Grip strength	Roberts <i>et</i> <i>al.</i> (2011)
J	Chair stand test (chair rise test)	Chair stand test (5-times sit-to-stand)	American Academy of Orthotists & Prosthetists







Low physical performance

2018 operational definition of sarcopenia

Low muscle strength

Low muscle quantity or quality

Low physical performance

Variable	Clinical practice	Research studies	Reference
Physical performance	Gait speed	Gait speed	NIH Toolbox 4 Meter Walk Gait Speed Test
	Short physical performance battery (SPPB)	SPPB	Short Physical Performance Battery Protocol NIH Toolbox
	Timed-up-and-go test (TUG)	TUG	Mathias (1986)
	400-meter walk or long- distance corridor walk (400-m walk)	400-m walk	Newman (2006)



AGENDA

- ✓ Sarcopenia: what are we talking about?
- Relationship between skeletal muscle and bone
- Sarcopenia a socio economic burden
- Conclusions








Sarcopenia and fractures












Sarcopenia and fractures





















Human skeletal muscle expresses VDR




- Regulation of calcium transport
- Uptake of inorganic phosphate for production of energy-rich
- phosphate compounds
- Protein synthesis








Vitamin D deficiency affects muscle protein synthesis in old rats














Cytokines and chemokines (myokines)	Ref.
IL-6	Pedersen et al., 2003
IL-7	Haugen et al., 2010
IL-8	Onan et al., 2009
IL-15	Quinn et al., 2009
Leukemia inhibitory factor (LIF)	Walker et al., 2010
Ciliary neurotrophic factor (CNTF)	Johnson et al., 2014
RANKL	Juffer et al., 2014
Myostatin.	Laurent MR 2015
Semaphorins	Henningsen et al., 2010

Growth factors	Ref.
Insulin-like growth factor 1 (IGF-1)	Hamrick et al., 2010,
IGF-2	Henningsen et al.2010
Fibroblast growth factor 2 (FGF-2)	Hamrick et al., 2010
FGF-21	Henningsen et al2010
TGF-β	Henningsen et al2010
PDGF	Henningsen et al2010
Connective tissue growth factor	Henningsen et al2010
Bone morphogenetic protein 1 (BMP1)	Henningsen et al2010

Matrix-related proteins	Ref.
Osteonectin	Chan et al., 2007, Henningsen et al., 2010
Matrix metalloproteinase 2 (MMP-2)	Chan et al., 2007, Henningsen et al., 2010
Cathepsins	Henningsen et al., 2010
Coagulation factors (tPA, uPA, TFPI,)	Henningsen et al., 2010



AGENDA

- ✓ Sarcopenia: what are we talking about?
- ✓ Relationship between skeletal muscle and bone
- Sarcopenia a socio economic burden
- Conclusions







Clinical effect of sarcopenia

UNIL | Université de Lausanne

Decreased muscle mass



Increased risk of falls



Further muscle loss



Fatigue



Reduced physical activity









Sarcopenia and disability

Rejected papers

- NotEWGSOP sarcopenia definition (n=20)
- Unadapted analysis (n=9)
- Paper written in Chinese (n=1)
- Incomplete data (n=4)
- Specific population (n=2)

4	
1.000	
of I have be only	
And the second second second	
() () () () () ()	- April 198
about 10 Pic.	Secretary Street, Sector
A Company	- 9%
440	
100	Bi-Miller
Decidences	CONTRACT SECTION
Internal Control (Co.)	Section Control
	programme and the second
	matcheropic.
personal security	
Trings served with a	
4	
And received parties of the Co.	

Study name		Statisti	cs for ea	ch study			Odds	ratio and	95% CI	
	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value					
Bianchi, 2015	4,890	2,677	8,931	5,164	0,000	1	1	1 -	-	T
Cawthon, 2015	2,420	1,495	3,917	3,597	0,000			-	F	- 1
Da Silva, 2014	2,260	1,124	4,545	2,287	0,022			-	-	- 1
Sanchez-Rodriguez, 2015	1,273	0,624	2,597	0,663	0,507			-		- 1
Tanimoto, 2013	12,820	6,059	27,125	6,671	0,000				-	- I
Wbo, 2015	2,100	1,591	2,772	5,239	0,000					- 1
	3,034	1,799	5,118	4,162	0,000	- 1	- 1	4		
						0,01	0,1	1	10	100



>17,000 participants





Sarcopenia and mortality

UNIL | Université de Lausanne

Rejected papers

- NotEWG9CP sarcopenia definition (n=20)
- Unadapted analysis (n=9)
- Paper written in Chinese (n=1)
- Incomplete data (n=4)
- Specific population (n=2)

4	
	Section of the control of the contro
transaction and a first or the second	

Study name	Statistics for each study					Odds ratio and 95% CI			
	Odds ratio	Lower	Upper limit	Z-Value	p-Value				
Arango-Lopera, 2013	1,866	0,978	3,561	1,892	0.059	1	T)	 	T = T
Bianchi, 2015	5,239	2,705	10,145	4,911	0,000				- I
Cawthon, 2015	4,580	3,501	5,992	11,101	0,000				
Cerri, 2015	12,133	2,815	52,300	3,348	0,001			350	
Da Silva, 2014	3,462	1,661	7,216	3,314	0,001			-	-1 1
Kim, 2014	2,360	1,153	4,833	2,349	0,019				1 1
Landi, 2012	3,873	1,572	9,542	2,943	0,003			-	- 1
Landi, 2013	2,992	1,465	6,111	3,008	0,003			-	1 1
Saka, 2015	2,964	1,364	6,441	2,743	0,006				1 1
Sanchez-Rodriguez, 2014	2,199	0,600	8,055	1,189	0,234			-	-
Vetrano, 2014	4,716	3,109	7,153	7,295	0,000			-	-
Woo, 2015	3,190	2,542	4,003	10,013	0,000				
	3,596	2,957	4,373	12,821	0,000	- 1	- 1		
						0,01	0,1	1	10 100

>17,000 participants





AGENDA

- ✓ Sarcopenia: what are we talking about?
- ✓ Relationship between skeletal muscle and bone
- ✓ Sarcopenia a socio economic burden
- Conclusions



















